Abstract:Graphical representation depicting the potential mechanism involved in FGF10‐mediated protection against AD‐like symptoms and pathologies in both in vivo 3xTg‐AD mice and in vitro APPswe‐transfected HT22 cells. The neuroprotective effects of FGF10 were tested via intranasal delivery and AAV9‐mediated systemic gene delivery methods. FGF10 stimulates the FGFR2/PI3K/AKT signaling pathway, leading to the upregulation of p‐GSK3β S9/GSK3β and Bcl‐2/Bax. This, in turn, reduces tau hyperphosphorylation and neuronal apoptosis, resulting in protection against neuronal damage and cognitive dysfunction in AD. Alzheimer's disease (AD) is characterized with senile plaques formed by Aβ deposition, and neurofibrillary tangles composed of hyperphosphorylated tau protein, which ultimately lead to cognitive impairment. Despite the heavy economic and life burdens faced by the patients with AD, effective treatments are still lacking. Previous studies have reported the neuroprotective effects of FGF10 in CNS diseases, but its role in AD remains unclear. In this study, we demonstrated that FGF10 levels were reduced in the serum of AD patients, as well as in the brains of 3xTg‐AD mice and APPswe‐transfected HT22 cells, suggesting a close relationship between FGF10 and AD. Further investigations revealed that intranasal delivery of FGF10 improved cognitive functions in 3xTg‐AD mice. Additionally, FGF10 treatment reduced tau hyperphosphorylation and neuronal apoptosis, thereby mitigating neuronal cell damage and synaptic deficits in the cortex and hippocampus of 3xTg‐AD mice, as well as APPswe‐transfected HT22 cells. Furthermore, we evaluated the therapeutic potential of FGF10 gene delivery for treating AD symptoms and pathologies. Tail vein delivery of the FGF10 gene using AAV9 improved cognitive and neuronal functions in 3xTg‐AD mice. Similarly, endogenous FGF10 overexpression ameliorated tau hyperphosphorylation and neuronal apoptosis in the cortex and hippocampus of 3xTg‐AD mice. Importantly, we confirmed that the FGFR2/PI3K/AKT signaling pathway was activated following intranasal FGF10 delivery and AAV9‐mediated FGF10 gene delivery in 3xTg‐AD mice and APPswe‐transfected HT22 cells. Knockdown of FGFR2 attenuated the protective effect of FGF10. Collectively, these findings suggest that intranasal delivery of FGF10 and AAV9‐mediated FGF10 gene delivery could be a promising disease‐modifying therapy for AD.

Afgf Promotes Neurite Growth by Regulating GSK3β-CRMP2 Signaling Pathway in Cortical Neurons Damaged by Amyloid-β.

Roles of Glycogen Synthase Kinase 3 in Alzheimer’s Disease

Fibroblast growth factor 1 regulates signaling via the glycogen synthase kinase-3beta pathway. Implications for neuroprotection

Stimulation of autophagy prevents amyloid-β peptide-induced neuritic degeneration in PC12 cells.

Gsk-3/Creb Pathway Involved in the Gx-50'S Effect on Alzheimer'S Disease

β-Amyloid impairs the regulation of N-methyl-D-aspartate receptors by glycogen synthase kinase 3

6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase Suppresses Neuronal Apoptosis by Increasing Glycolysis and “Cyclin-Dependent Kinase 1-Mediated Phosphorylation of P27 after Traumatic Spinal Cord Injury in Rats

Neuron and Microglia/macrophage-Derived FGF10 Activate Neuronal FGFR2/PI3K/Akt Signaling and Inhibit Microglia/macrophages TLR4/NF-κB-dependent Neuroinflammation to Improve Functional Recovery after Spinal Cord Injury.

GSK‐3α/β‐mediated Phosphorylation of CRMP‐2 Regulates Activity‐dependent Dendritic Growth

Fibroblast growth factor 10 ameliorates neurodegeneration in mouse and cellular models of Alzheimer's disease via reducing tau hyperphosphorylation and neuronal apoptosis

Neuroprotective effects of regulators of the glycogen synthase kinase-3beta signaling pathway in a transgenic model of Alzheimer's disease are associated with reduced amyloid precursor protein phosphorylation

Blockage of GSK3β-mediated Drp1 phosphorylation provides neuroprotection in neuronal and mouse models of Alzheimer's disease.

Blocking GSK3β-mediated Dynamin1 Phosphorylation Enhances BDNF-dependent TrkB Endocytosis and the Protective Effects of BDNF in Neuronal and Mouse Models of Alzheimer's Disease

C6 Glioma-Secreted NGF and FGF2 Regulate Neuronal APP Processing Through Up-Regulation of ADAM10 and Down-Regulation of BACE1, Respectively

Ginsenoside Rg1 Protects Against Neurodegeneration by Inducing Neurite Outgrowth in Cultured Hippocampal Neurons

GLP-1 Receptor Agonists Downregulate Aberrant GnT-III Expression in Alzheimer's Disease Models Through the Akt/GSK-3β/β-catenin Signaling.

A method for the expression of fibroblast growth factor 14 and assessment of its neuroprotective effect in an Alzheimer's disease model

Β-Amyloid Redirects Norepinephrine Signaling to Activate the Pathogenic GSK3β/tau Cascade.

Activation of AKT1/GSK-3β/β-Catenin–TRIM11/Survivin Pathway by Novel GSK-3β Inhibitor Promotes Neuron Cell Survival: Study in Differentiated SH-SY5Y Cells in OGD Model

The Protection of Acetylcholinesterase Inhibitor on Β-Amyloid-induced the Injury of Neurite Outgrowth Via Regulating Axon Guidance Related Genes Expression in Neuronal Cells.

GSK-3β Deletion in Dentate Gyrus Excitatory Neuron Impairs Synaptic Plasticity and Memory